RIGL
Rigel Pharmaceuticals Inc
48.80$
+3.7%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +250.2% | -29.5% | -78.0% | +892.6% | +33.2% | +83.2% | +37.4% | -19.4% | -2.8% | +53.4% | +64.1% | |
| – | -7.2% | +1.0% | -27.1% | -99.4% | +215.7% | -1.2% | +21.0% | +61.5% | +306.5% | +162.3% | +5.2% | |
| – | – | – | – | – | +32.0% | +84.5% | +37.5% | -20.0% | -7.4% | +46.3% | +71.0% | |
| – | -7.2% | +1.0% | -27.1% | +1.4% | +12.8% | +13.6% | +8.5% | -7.6% | -59.3% | -4.7% | +42.4% | |
| – | -44.0% | +17.4% | +80.9% | +85.0% | +6.6% | +2.7% | +20.0% | +22.4% | -1.2% | +1.8% | +2.5% | |
| – | -19.0% | +11.8% | -6.7% | +39.0% | +9.0% | +7.2% | +17.5% | +8.3% | -25.2% | +4.7% | +9.3% | |
| – | – | – | – | – | – | – | – | – | – | – | +418.6% | |
| – | – | – | – | – | – | +303.9% | +259.2% | -23.7% | +85.4% | +15.2% | -7.6% | |
| – | – | – | – | – | – | – | – | – | – | – | +563.3% | |
| – | – | – | -148.5% | – | -115.8% | – | -6.5% | +399.7% | -24.8% | -61.2% | -27,931.7% | |
| – | – | – | – | – | – | – | – | – | – | – | +1,999.1% | |
| – | – | – | – | – | – | – | – | – | – | – | +361.4% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.